The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.
The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.
The objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.

开始日期2020-11-23

申办/合作机构

Intervene Immune, Inc.

100 项与 Intervene Immune, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Intervene Immune, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Intervene Immune, Inc. 相关的文献（医药）

2020-06-28·Aging3区 · 医学

Reversing immunosenescence for prevention of COVID-19

3区 · 医学

Article

作者: Fahy, Gregory M. ; Brooke, Robert T.

2018-01-23·Proceedings of the National Academy of Sciences1区 · 综合性期刊

Questioning the inevitability of aging

1区 · 综合性期刊

Letter

作者: Fahy, Gregory M. ; Mitteldorf, Josh

Paul Nelson and Joanna Masel (1) are the most recent theorists to bypass evolution and seek an abstract answer to the question, “What is the cause of aging?” Their mathematics is not in question, but the process of somatic evolution that they model bears no obvious relation to aging as it has been characterized in humans. Regrettably, their result has been caricatured in the popular press to discredit medical research toward delayed aging. The Nelson/Masel theory applies to multicellular life, but aging first evolved in bacteria (2) and then in protists (3). The genetics of aging in protists is homologous to … [↵][1]1To whom correspondence should be addressed. Email: aging.advice{at}gmail.com. [1]: #xref-corresp-1-1

项与 Intervene Immune, Inc. 相关的新闻（医药）

2022-06-08

·PRNewswire

Anti-aging Therapeutics Market worth $ 2013.5 Million by 2030 - Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 8, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others), Mechanism of Action (Senolytic, Cell Regeneration, mTOR inhibitor/Modulator, AMP-kinase/AMP Activator, Mitochondria Inhibitor/Modulator and Others))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030" According to the latest research by InsightAce Analytic, the global Anti-aging Therapeutics market size valued at US$ 518.86 million in 2021, and it is expected to reach US$ 2013.51 million in 2030, recording a promising CAGR of 16.53% during the period of 2022-2030. Request for Sample Pages: Aging populations are increasing the prevalence of age-related illnesses, causing individual and social concerns. The demand for effective regenerative medicine solutions for the elderly is higher than ever. Anti-Aging Therapeutics has emerged as a new medical science field. Anti-aging diagnosis and medicine, which is a subset of medical and healthcare, uses modern science and medical technology to identify, prevent, cure, and reverse age-related dysfunctions, illnesses, and diseases. Several cell, insect, and animal models may be useful beginning areas in the development of anti-aging medicines prior to human trials. Interest and expenditure in anti-aging medicines are rising exponentially as living conditions improve. Several companies have also focused their efforts on stem cells and regenerative medicine. Given the numerous applications of stem cells, applications in regenerative medicine are far beyond ageing disorders and illnesses. Nonetheless, a few organizations have concentrated specifically on age-related problems. For instance, In Feb 2021, Cambrian Biopharma received $60 million in private funding for the development of anti-aging medications. The "Nine Hallmarks of Aging," which include cellular senescence, persistent tissue inflammation, and mitochondrial malfunction, are the focus of research of Cambrian scientists. Researchers are utilizing advancements in immunology, genomics, and epigenetics, as well as technologies ranging from gene editing to novel stem cell treatments. There is substantial potential for anti-aging therapeutics companies that effectively launch longevity treatments. Despite these encouraging breakthroughs in the field of ageing, a number of barriers will become obvious once an anti-aging medicine undergoes the demanding clinical trial procedure. Market growth is primarily related to a rise in demand for individualized, precise, preventative, and participative ageing therapies, as well as an increase in the Geriatric Population. As a result, as the number of the elderly rises, so does the need for anti-aging treatments. Increased technological advancements and R&D spending on anti-ageing products are propelling the market forward. To meet the growing demand for technologically advanced solutions among customers, companies in the field have mainly developed revolutionary anti-ageing therapeutics products. With a rising healthcare industry, North America is expected to have the largest revenue shares in 2022. Research and development into pharmaceuticals are rising in major economies such as the United States and Canada, and this is due to the increased investment in pharmaceutical design, production as well as research into senescent cells. Moreover, Asia Pacific is the world's most populous region, and it has a sizable market for anti-aging therapeutics. The ever-increasing proportion of elderly people in the population is a potential customer base for anti-aging treatments, driving regional growth. Enquiry Before Buy: Major key Players in the Anti-aging Therapeutics market are AgelessRx, ANOVA Institute for Regenerative Medicine, Betterhumans, BioAge Labs, BIOPHYTIS BSA, bioXcellerator, Cambrian Biopharma, CytoMed Therapeutics, Gero.ai, Rejuvenate Bio, Rejenevie Therapeutics, UT Health San Antonio, MyMD Pharmaceuticals, Intervene Immune, Inc. , CohBar, Inc., Alkahest, Athersys Inc, BHB Therapeutics, Biosplice, Cyclo Therapeutics, Denali Therapeutics, Elysium Health, Genome Protection, GenSight Biologics, Intervene Immune, Khondrian, Longeveron, LyGenesis, Mesoblast, Minovia Therapeutics, Mitobridge, Navitor Pharmaceuticals, NeuroTrack, Nuchido, NuSirt, OneSkin Technologies, PharmatrophiX, Proteostasis Therapeutics, Retrotope, Stealth Biotherapeutics, TA Sciences, Unity Biotechnology Younger Phenotype, and Other Prominent Players Recent Key Developments: In Feb 2022, Cambrian Biopharma announced that it had entered into a licence arrangement with Novartis to promote innovative, selective drugs that target the mechanistic target of rapamycin (mTOR) pathway. These compounds were conceived and characterized by Novartis. Cambrian Biopharma informed via a statement that the licensed assets are structural analogues of the FDA-approved drug rapamycin. This drug has been shown to prevent or reverse multiple age-related health deficits in mice and to extend their average lifespan by up to 31 %, according to the information provided by Cambrian Biopharma. In May 2019, Rejenevie™ Therapeutics announced the initiation of the Company's Phase II clinical trial to explore the safety and effectiveness of its unique AR-100 immune restoration treatment to increase the function of the ageing immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration medicines targeting age-related disorders. In April 2022, MyMD Pharmaceuticals Inc. accelerated the dosing of additional patients in the Company's fully funded Phase 2 clinical study of lead drug candidate MYMD-1 as a treatment for delaying ageing and extending a healthy lifespan. The double-blind, placebo-controlled, randomized Phase 2 research (NCT05283486) explores the effectiveness, safety, and pharmacokinetics of MYMD-1® in the treatment of people aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Molecule Biologics Small Molecules Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Aging Cellular Aging Immune Aging Metabolic Aging Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Mechanism of Action Senolytic Cell Regeneration mTOR inhibitor/Modulator AMP-kinase/AMP Activator Mitochondria Inhibitor/Modulator Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 U.S. Canada Europe Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Germany France Italy Spain Russia Rest of Europe Asia Pacific Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 India China Japan South Korea Australia & New Zealand Latin America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Brazil Mexico Rest of Latin America Middle East & Africa Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for global Anti-aging Therapeutics market To receive industry overview and future trends of global Anti-aging Therapeutics market To analyse the Anti-aging Therapeutics market drivers and challenges To get information on Anti-aging Therapeutics market size value (US$ Mn) forecast till 2030 Major Investments, Mergers & Acquisition in global Anti-aging Therapeutics market industry For Customization @ Other Related Reports Published by InsightAce Analytic: Global Longevity and Anti-Senescence Therapy Market Global Antisense Oligonucleotide Therapeutics Market Global Anti-Ageing Products Services and Devices Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ SOURCE InsightAce Analytic Pvt. Ltd.

寡核苷酸小分子药物并购

100 项与 Intervene Immune, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Intervene Immune, Inc. 相关的转化医学

登录后查看更多信息